LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced today that it was promoting Robert Clarke, PhD, to the role of Chief Scientific Officer (CSO) and Vice President of Research and Development effective immediately. Dr. Clarke has been overseeing the company’s research efforts and has been pivotal in the development of Pulmatrix’s inhaled therapeutic technologies since joining the company in 2004, shortly after the company was founded in 2003. He will continue to report to Robert Connelly, President and CEO of Pulmatrix.
